… Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares LEIDEN, The Netherlands, … 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, the Netherlands … available on the SEC's website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands and … NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands … are available on the SEC’s website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… USA. In addition to our global presence, ProQR operates through a legal entity in China to support local … a difference in the lives of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables … inform your health - but never limit it. Department: Development Location: Shanghai The Role: As Project Lead, IIT …
… for our liver programs, driving the discovery and development of novel RNA-based drug candidates for chronic … Science, and the Chief Scientific Officer to identify and develop new opportunities, optimize our portfolio, and ensure scientific …
… AX-1412 B4GALT1 Cardiovascular disease 2025 update on optimization for GalNAc delivery Continue to execute on … milestone income from the existing partnership, and an option to exercise for an additional five targets for … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. Financial Highlights At June 30, …
… B4GALT1 for Cardiovascular diseases mid-2025 update on optimization for GalNAc delivery Continue to execute on … milestone income from the existing partnership, and an option to exercise for an additional five targets for … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical cataly